Signal Advisors Wealth LLC Invests $645,000 in Health Catalyst, Inc. $HCAT

Key Points

• Signal Advisors Wealth LLC acquired a new stake in Health Catalyst, Inc. (NASDAQ: HCAT), purchasing 171,207 shares valued at approximately $645,000 during the 2nd quarter.
• Health Catalyst's stock has fallen by 4.3% to $2.89, with a 1-year low of $2.52 and a high of $9.24, and the company has a market capitalization of $203.37 million.
• Multiple analysts, including those from BTIG Research and Cantor Fitzgerald, have reiterated a "neutral" rating on Health Catalyst, with price targets significantly reduced, indicating uncertainty in the stock's future performance.

Signal Advisors Wealth LLC purchased a new stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 171,207 shares of the company's stock, valued at approximately $645,000. Signal Advisors Wealth LLC owned approximately 0.25% of Health Catalyst at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of HCAT. SG Americas Securities LLC raised its position in shares of Health Catalyst by 195.2% in the first quarter. SG Americas Securities LLC now owns 80,825 shares of the company's stock valued at $366,000 after buying an additional 53,443 shares during the last quarter. Invesco Ltd. increased its position in Health Catalyst by 22.2% during the first quarter. Invesco Ltd. now owns 97,599 shares of the company's stock worth $442,000 after purchasing an additional 17,725 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Health Catalyst during the fourth quarter worth approximately $735,000. Petrus Trust Company LTA acquired a new position in Health Catalyst during the first quarter worth approximately $432,000. Finally, Whetstone Capital Advisors LLC acquired a new position in Health Catalyst during the first quarter worth approximately $7,724,000. Hedge funds and other institutional investors own 85.00% of the company's stock.

Analyst Upgrades and Downgrades

HCAT has been the subject of several recent research reports. Citigroup lowered shares of Health Catalyst from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $6.50 to $3.50 in a research report on Friday, August 8th. Summit Redstone set a $5.00 target price on shares of Health Catalyst in a research note on Friday, August 29th. Stifel Nicolaus decreased their target price on shares of Health Catalyst from $5.50 to $4.50 and set a "hold" rating for the company in a research note on Friday, August 8th. BTIG Research restated a "neutral" rating on shares of Health Catalyst in a research note on Friday, September 5th. Finally, Canaccord Genuity Group decreased their target price on shares of Health Catalyst from $9.00 to $5.00 and set a "buy" rating for the company in a research note on Friday, August 29th. Three research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, Health Catalyst presently has a consensus rating of "Hold" and an average target price of $4.73.

Health Catalyst Stock Up 1.2%

HCAT traded up $0.04 on Tuesday, reaching $2.99. 80,431 shares of the company traded hands, compared to its average volume of 723,452. The stock's 50 day moving average price is $3.39 and its 200-day moving average price is $3.79. Health Catalyst, Inc. has a 52-week low of $2.52 and a 52-week high of $9.24. The company has a market cap of $210.05 million, a price-to-earnings ratio of -1.98 and a beta of 1.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.83 and a quick ratio of 1.83.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.